Michael Mano

This profile gathers the share dealings of Michael Mano in Karyopharm Therapeutics Inc., where the filings describe the role as senior executive. Over a trading history stretching from 28 February 2022 to 13 May 2026, the count stands at 15 filings.

The open-market record consists of 5 sales worth €71k, with no purchase. Other entries cover 10 share grants. 2026 to date brings no purchases and 1 sale.

The newest entry dates from 15 May 2026: a share grant, in Karyopharm Therapeutics Inc. The median gap between a trade and its publication by SEC (Form 4) is 2 days. US insiders must file a Form 4 within two business days of a trade. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.